NEW YORK ( TheStreet) -- CHANGE IN RATINGS
Assurant (AIZ) downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Valuation call.
Akamai Technologies (AKAM - Get Report) upgraded at Jefferies to Hold from Underperform, Jefferies said. $36 price target. Additional performance from ecommerce seasonality and less relative exposure to Europe.Abercrombie & Fitch (ANF) downgraded at Brean Murray from Buy to Hold, Brean Murray said. Estimates also cut, given lower expected margins. Broadcom (BRCM - Get Report) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. Chip stocks should outperform the market this year, as industry fundamentals improve. Coeur D'Alene (CDE - Get Report) downgraded at BMO to Market Perform, BMO Capital said. $32.50 price target. Company is facing lower silver prices. CME Group (CME - Get Report) downgraded at Evercore from Overweight to Equal-weight, Evercore Partners said. $250 price target. MF Global damages could have a long-term business effect. Concur Technologies (CNQR) downgraded at Jefferies to Hold from Buy, Jefferies said. Estimates also lowered on demand and FX headwinds. Fairchild Semiconductor (FCS) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $15 price target. Growth should reaccelerate later in 2012. First Horizon (FHN) downgraded at BofA/Merrill from Neutral to Underperform, Bank of America/Merrill Lynch said. $7 price target. Company lacks near-term catalysts. Fossil (FOSL) upgraded at Brean Murray from Hold to Buy, Brean Murray said. $100 price tagret. Stock is attractively valued, following its recent decline. Huntington Bancshares (HBAN) downgraded at Guggenheim from Buy to Neutral, Guggenheim said. Valuation call. Hartford Financial (HIG) upgraded at Goldman from Neutral to Buy, Goldman Sachs said. Different multi-line strategy could help unlock value. Informatica (INFA) downgraded at BMO from Outperform to Market Perform, BMO Capital Markets said. $35 price target. Overall software spending, especially for larger middleware projects, slowed in the second half of November. Impax Laboratories (IPXL) upgraded at Canaccord from Hold to Buy, Canaccord Genuity said. $28 price target. Stock could be at a positive inflection point. JC Penney (JCP) upgraded at Deutsche from Sell to Hold, Deutsche Bank said. $32 price target. New management is restructuring, but large changes are necessary.